HSV-1 gB Inhibitors

HSV-1 gB inhibitors are chemicals designed to disrupt the function or expression of glycoprotein B (gB) of Herpes Simplex Virus type 1 (HSV-1). gB is a crucial glycoprotein that facilitates the entry of the virus into host cells, making it a prime target for antiviral interventions. The inhibition strategies can be direct, targeting the gB protein itself, or indirect, affecting the viral lifecycle stages that influence gB functionality. Direct inhibitors, such as Docosanol and BILS 179 BS, primarily function by interrupting the interaction between the viral gB protein and host cell receptors. This disruption prevents the fusion of the viral envelope with the cell membrane, a critical step for viral entry. Such inhibitors are particularly valuable as they directly target the initial stages of infection, potentially reducing the viral load and spread.

Indirect inhibitors comprise a broader range of compounds, predominantly targeting the viral replication process. Agents like Acyclovir, Valacyclovir, Penciclovir, and their prodrugs, Famciclovir and Valacyclovir, are nucleoside analogs that target viral DNA polymerase. By inhibiting this enzyme, these drugs prevent the replication of viral DNA, subsequently reducing the expression and functionality of viral proteins, including gB. This reduction in viral replication not only impacts the initial infection phase but also the spread of the virus to new cells. Other indirect inhibitors, such as Maribavir and Cidofovir, work by targeting different aspects of the viral lifecycle. Maribavir inhibits the UL97 kinase, which is involved in viral maturation, thus affecting the virus's ability to initiate a subsequent infection cycle effectively. Cidofovir, like the nucleoside analogs, targets the viral DNA polymerase, offering a similar mode of indirect inhibition.